Trials / Completed
CompletedNCT00098046
Famciclovir Oral Pediatric Formulation in Children 1-12 Years of Age With Varicella Zoster Infection
Pharmacokinetics and Safety of Famciclovir Oral Pediatric Formulation in Children 1-12 Years of Age With Varicella Zoster Infection
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 76 (estimated)
- Sponsor
- Novartis · Industry
- Sex
- All
- Age
- 1 Year – 12 Years
- Healthy volunteers
- Not accepted
Summary
Varicella zoster virus causes chickenpox in children and shingles in adults. Chickenpox is usually a self-limiting illness characterized by fever and a rash. Serious complications can include secondary bacterial infections, pneumonia, and encephalitis. Anti-viral treatment is not a standard of care in immunocompetent children, but is recommended whenever a risk of complication exists. This study will evaluate the safety and blood levels of a new formulation of famciclovir in children 1-12 years of age.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | famciclovir |
Timeline
- Start date
- 2005-07-01
- Completion
- 2007-07-01
- First posted
- 2004-12-03
- Last updated
- 2007-09-26
Locations
5 sites across 4 countries: United States, Costa Rica, Guatemala, Panama
Source: ClinicalTrials.gov record NCT00098046. Inclusion in this directory is not an endorsement.